Population-Based Surveillance for Rare Congenital and Inherited Disorders: Models and Challenges

  • Jodi M. Jackson
  • Krista S. Crider
  • Richard S. Olney
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 686)

Abstract

Worldwide, an estimated 7.9 million children are affected by congenital and inherited disorders. Some disorders are relatively common, affecting tens of thousands of newborns annually; others are rare, involving disorders that, in extreme cases, can affect less than 30 infants per year. However, this infrequency does not reduce the impact or burden on individuals and their families. Congenital defects can cause long-term disability, have a lifelong impact on health, and cost billions of dollars in care. Collection of population-based surveillance data ideally enables the discovery of etiologies for rare congenital disorders of unknown cause, allows for examining outcomes, and evaluating treatments and interventions for children with all types of congenital and inherited disorders. Many challenges are associated with performing population-based surveillance, such as difficulty in ascertaining appropriate diagnoses and frequent unavailability of necessary resources. This chapter focuses on the importance of population-based data and uses national and international surveillance systems as models for how these rare disorders can be better understood.

Keywords

Population surveillance Rare diseases Congenital abnormalities Genetic diseases 

References

  1. 1.
    Bailey DB Jr, Raspa M, Bishop E et al (2009) No change in the age of diagnosis for Fragile X Syndrome: findings from a national parent survey. Pediatrics 124:527–533PubMedCrossRefGoogle Scholar
  2. 2.
    Botto LD, Lisi A, Bower C et al (2006) Trends of selected malformations in relation to folic acid recommendations and fortification: an international assessment. Birth Defects Res A Clin Mol Teratol 76:693–705PubMedCrossRefGoogle Scholar
  3. 3.
    Botto LD, Mastroiacovo P (2000) Surveillance for Birth Defects and Genetic Diseases. In: Khoury MJ, Burke W, Thomson EJ (eds) Genetics and Public Health in the 21st Century, Oxford University Press, OxfordGoogle Scholar
  4. 4.
    Botto LD, Robert-Gnansia E, Siffel C et al (2006) Fostering international collaboration in birth defects research and prevention: a perspective from the International Clearinghouse for Birth Defects Surveillance and Research. Am J Public Health 96:774–780PubMedCrossRefGoogle Scholar
  5. 5.
    Bradley D, Parsons E (1995) Newborn screening for Duchenne muscular dystrophy. Semin Neonatol 2:27–34Google Scholar
  6. 6.
    Canfield MA, Collins JS, Botto LD et al (2005) Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: findings from a multi-state population-based study. Birth Defects Res A Clin Mol Teratol 73:679–689PubMedCrossRefGoogle Scholar
  7. 7.
    Centers for Disease Control and Prevention (CDC) (1998) Mortality among children with sickle cell disease identified by newborn screening during 1990–1994 – California, Illinois, and New York. MMWR Morb Mortal Wkly Rep 47:169–172Google Scholar
  8. 8.
    Centers for Disease Control and Prevention (CDC) (2000) Update: newborn screening for sickle cell disease – California, Illinois, and New York, 1998. MMWR Morb Mortal Wkly Rep 49:729–731Google Scholar
  9. 9.
    Centers for Disease Control and Prevention (CDC) (2001) Using tandem mass spectrometry for metabolic disease screening among newborns. A report of a work group, MMWR Recomm Rep 50:1–34Google Scholar
  10. 10.
    Centers for Disease Control and Prevention (CDC) (2007) Hospital stays, hospital charges, and in-hospital deaths among infants with selected birth defects – United States, 2003. MMWR Morb Mortal Wkly Rep 56:25–29Google Scholar
  11. 11.
    Centers for Disease Control and Prevention (CDC) (2008) Impact of expanded newborn screening – United States, 2006. MMWR Morb Mortal Wkly Rep 57:1012–1015Google Scholar
  12. 12.
    Christianson A, Howson CP, Modell B (2006) March of Dimes Global Report on Birth Defects, the hidden toll of dying and disabled children, March of Dimes Birth Defects Foundation, White Plains, NYGoogle Scholar
  13. 13.
    Clague A, Thomas A (2002) Neonatal biochemical screening for disease. Clin Chim Acta 315:99–110PubMedCrossRefGoogle Scholar
  14. 14.
    Coffee B, Keith K, Albizua I et al (2009) Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 85:503–514PubMedCrossRefGoogle Scholar
  15. 15.
    Colorado Department of Public Health and Environment, Colorado Responds to Children with Special Needs, http://www.cdphe.state.co.us/dc/crcsn/, Accessed September, 2009
  16. 16.
    Correa A, Cragan, JD, Kucik JE et al (2007) Metropolitan Atlanta Congenital Defects Program 40th Anniversary Edition Surveillance Report. Birth Defects Res A Clin Mol Teratol 79Google Scholar
  17. 17.
    Crawford DC, Acuna JM, Sherman SL (2001) FMR1 and the Fragile X syndrome: human genome epidemiology review. Genet Med 3:359–371PubMedCrossRefGoogle Scholar
  18. 18.
    Cystic Fibrosis Foundation (2008) 2007 Annual Data Report, BethesdaGoogle Scholar
  19. 19.
    Cystic Fibrosis Foundation (2009) All fifty states to screen newborns for cystic fibrosis by 2010Google Scholar
  20. 20.
    Cystic Fibrosis Mutation Database, CFMDB Statistics, http://www.genet.sickkids.on.ca/cftr/StatisticsPage.html, Accessed September, 2009
  21. 21.
    Davis H, Schoendorf KC, Gergen PJ et al (1997) National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health 87:1317–1322PubMedCrossRefGoogle Scholar
  22. 22.
    Division of Family Health Services New Jersey Department of Health and Senior Services, Special Child and Adult Health Services (1997) Long term tracking of children with sickle cell disease and other hemoglobinopathies. New Jersey Department of Health and Senior Services, TrentonGoogle Scholar
  23. 23.
    Erickson JD, Mulinare J, McClain PW et al (1984) Vietnam veterans’ risks for fathering babies with birth defects. JAMA 252:903–912PubMedCrossRefGoogle Scholar
  24. 24.
    Franks ME, Macpherson GR, Figg WD (2004) Thalidomide. Lancet 363:1802–1811PubMedCrossRefGoogle Scholar
  25. 25.
    Garber KB, Visootsak J, Warren ST (2008) Fragile X syndrome. Eur J Hum Genet 16:666–672PubMedCrossRefGoogle Scholar
  26. 26.
    Gaston MH, Verter JI, Woods G et al (1986) Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 314:1593–1599PubMedCrossRefGoogle Scholar
  27. 27.
    Gill FM, Sleeper LA, Weiner SJ et al (1995) Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 86:776–783PubMedGoogle Scholar
  28. 28.
    Grosse SD, Khoury MJ, Greene CL et al (2006) The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med 8:205–212PubMedCrossRefGoogle Scholar
  29. 29.
    Guthrie R (1992) The origin of newborn screening. Screening 1:5–15PubMedCrossRefGoogle Scholar
  30. 30.
    Hoff T, Ayoob M, Therrell BL (2007) Long-term follow-up data collection and use in state newborn screening programs. Arch Pediatr Adolesc Med 161:994–1000PubMedCrossRefGoogle Scholar
  31. 31.
    Hoff T, Hoyt A, Therrell B et al (2006) Exploring barriers to long-term follow-up in newborn screening programs. Genet Med 8:563–570PubMedCrossRefGoogle Scholar
  32. 32.
    Honein MA, Kirby RS, Meyer RE et al (2009) The association between major birth defects and preterm birth. Matern Child Health J 13:164–175PubMedCrossRefGoogle Scholar
  33. 33.
    Hoogerwaard EM, van der Wouw PA, Wilde AA et al (1999) Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 9:347–351PubMedCrossRefGoogle Scholar
  34. 34.
    Hoyert DL, Mathews TJ, Menacker F et al (2006) Annual summary of vital statistics: 2004. Pediatrics 117:168–183PubMedCrossRefGoogle Scholar
  35. 35.
    International Clearninghouse for Birth Defects Surveillance and Research (2009) http://www.icbdsr.org, Accessed September
  36. 36.
    Iowa Registry for Congenital and Inherited Disorders, Birth Defects Data and Statistics, http://www.public-health.uiowa.edu/ircid/, Accessed September, 2009
  37. 37.
    Joy P, Black C, Rocca A et al (2009) Neuropsychological functioning in children with medium chain acyl coenzyme a dehydrogenase deficiency (MCADD): the impact of early diagnosis and screening on outcome. Child Neuropsychol 15:8–20PubMedCrossRefGoogle Scholar
  38. 38.
    Kemper AR, Boyle CA, Aceves J et al (2008) Long-term follow-up after diagnosis resulting from newborn screening: statement of the US Secretary of Health and Human Services’ Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Genet Med 10:259–261PubMedCrossRefGoogle Scholar
  39. 39.
    Kemper AR, Wake MA (2007) Duchenne muscular dystrophy: issues in expanding newborn screening. Curr Opin Pediatr 19:700–704PubMedCrossRefGoogle Scholar
  40. 40.
    Kerem E, Corey M, Kerem BS et al (1990) The relation between genotype and phenotype in cystic fibrosis – analysis of the most common mutation (delta F508). N Engl J Med 323:1517–1522PubMedCrossRefGoogle Scholar
  41. 41.
    Leikin SL, Gallagher D, Kinney TR et al (1989) Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 84:500–508PubMedGoogle Scholar
  42. 42.
    Li S, Moore CA, Li Z et al (2003) A population-based birth defects surveillance system in the People’s Republic of China. Paediatr Perinat Epidemiol 17:287–293PubMedCrossRefGoogle Scholar
  43. 43.
    Maier EM, Gersting SW, Kemter KF et al (2009) Protein misfolding is the molecular mechanism underlying MCADD identified in newborn screening. Hum Mol Genet 18:1612–1623PubMedCrossRefGoogle Scholar
  44. 44.
    Mathews TJ, MacDorman MF (2008) Infant mortality statistics from the 2005 period linked birth/infant death data set. Natl Vital Stat Rep 57:1–32PubMedGoogle Scholar
  45. 45.
    McKone EF, Emerson SS, Edwards KL et al (2003) Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 361:1671–1676PubMedCrossRefGoogle Scholar
  46. 46.
    National Birth Defect Prevention Network (NBDPN) (June 2004) Guidelines for conducting birth defects surveillance, L.E. Sever, National Birth Defects Prevention Network, Inc., Atlanta, GAGoogle Scholar
  47. 47.
    National Coordinating Center for the Genetics and Newborn Screening Regional Collaborative Groups (2009) http://www.nccrcg.org, Accessed September, 2009
  48. 48.
    National Newborn Screening and Genetics Resource Center, National Newborn Screening Information System, http://www2.uthscsa.edu/nnsis/, Accessed September 2009
  49. 49.
    Newborn Screening Task Force American Academy of Pediatrics (2000) Serving the family from birth to the medical home. Newborn screening: a blueprint for the future – a call for a national agenda on state newborn screening programs. Pediatrics 106:389–422Google Scholar
  50. 50.
    Newborn screening: toward a uniform screening panel and system (2006). Genet Med 8(Suppl 1):1S–252SGoogle Scholar
  51. 51.
    Olney RS (2000) Newborn screening for sickle cell disease: public health impact and evaluation. In: Khoury MJ, Burke W, Thomson EJ (eds) Genetics and Public Health in the 21st Century. Oxford University Press, OxfordGoogle Scholar
  52. 52.
    Panny S (1997) The Maryland sickle cell disease program: evaluating program effectiveness, in 1997 National Sickle Cell Disease Conference, Washington, DCGoogle Scholar
  53. 53.
    Parker SE, Mai CT, Strickland MJ et al (2009) Multistate study of the epidemiology of clubfoot. Birth Defects Res A Clin Mol Teratol 85(11):897–904Google Scholar
  54. 54.
    Pauling L, Itano HA et al (1949) Sickle cell anemia a molecular disease. Science 110:543–548PubMedCrossRefGoogle Scholar
  55. 55.
    Platt OS, Brambilla DJ, Rosse WF et al (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639–1644PubMedCrossRefGoogle Scholar
  56. 56.
    Politano L, Nigro V, Nigro G et al (1996) Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA 275:1335–1338PubMedCrossRefGoogle Scholar
  57. 57.
    Population-based birth defects surveillance data from selected states (2008) 2001–2005. Birth Defects Res A Clin Mol Teratol 82:831–961Google Scholar
  58. 58.
    Reller MD, Strickland MJ, Riehle-Colarusso T et al (2008) Prevalence of congenital heart defects in metropolitan Atlanta, 1998–2005. J Pediatr 153:807–813PubMedCrossRefGoogle Scholar
  59. 59.
    Riordan JR, Rommens JM, Kerem B et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073PubMedCrossRefGoogle Scholar
  60. 60.
    Seligman PJ, Matte TD (1991) Case definitions in public health. Am J Public Health 81:161–162PubMedCrossRefGoogle Scholar
  61. 61.
    Shafer FE, Lorey F, Cunningham GC et al (1996) Newborn screening for sickle cell disease: 4 years of experience from California’s newborn screening program. J Pediatr Hematol Oncol 18:36–41PubMedCrossRefGoogle Scholar
  62. 62.
    Shin M, Besser LM, Siffel C, Kucik JE, Shaw GM, Lu C, Correa A, and the Congenital Anomaly Multistate Prevalence and Survival (CAMPS) Collaborative, Prevalence of children and adolescents with spina bifida in 10 regions of the United States, (submitted)Google Scholar
  63. 63.
    Soucie JM, Evatt B, Jackson D (1998) Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 59:288–294PubMedCrossRefGoogle Scholar
  64. 64.
    Soucie JM, Symons J 4th, Evatt B et al (2001) Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 7:198–206PubMedCrossRefGoogle Scholar
  65. 65.
    Soucie JM, Nuss R, Evatt B et al (2007) Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 96:437–442Google Scholar
  66. 66.
    Sox CM, Cooper WO, Koepsell TD et al (2003) Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease. JAMA 290:1057–1061PubMedCrossRefGoogle Scholar
  67. 67.
    Sutton PD, Tejada-Vera B (2009) Births, marriages, divorces and deaths: provisional data for 2008, National Center for Health Statistics, HyattsvilleGoogle Scholar
  68. 68.
    Texas Department of State Health Services (2007) Texas Health Data, Birth Defects Data, http://soupfin.tdh.state.tx.us/bdefdoc.htm, Accessed September 2009
  69. 69.
    Therrell BL, Panny SR, Davidson A et al (1992) U.S. newborn screening system guidelines: statement of the Council of Regional Networks for Genetic ServicesGoogle Scholar
  70. 70.
    Tolarova MM, Cervenka J (1998) Classification and birth prevalence of orofacial clefts. Am J Med Genet 75:126–137PubMedCrossRefGoogle Scholar
  71. 71.
    Turner G, Webb T, Wake S et al (1996) Prevalence of fragile X syndrome. Am J Med Genet 64:196–197PubMedCrossRefGoogle Scholar
  72. 72.
    Vichinsky E, Hurst D, Earles A et al (1998) Newborn screening for sickle cell disease: effect on mortality. Pediatrics 81:749–755Google Scholar
  73. 73.
    Wilcken B, Haas M, Joy P et al (2007) Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369:37–42PubMedCrossRefGoogle Scholar
  74. 74.
    Wilcken B, Haas M, Joy P et al (2009) Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 124: e241–248PubMedCrossRefGoogle Scholar
  75. 75.
    Yoon PW, Olney RS, Khoury MJ et al (1997) Contribution of birth defects and genetic diseases to pediatric hospitalizations. A population-based study. Arch Pediatr Adolesc Med 151:1096–1103PubMedCrossRefGoogle Scholar
  76. 76.
    Yoon PW, Rasmussen SA, Lynberg MC et al (2001) The National Birth Defects Prevention Study. Public Health Rep 116(Suppl 1):32–40PubMedCrossRefGoogle Scholar

Copyright information

© Springer Netherlands 2010

Authors and Affiliations

  • Jodi M. Jackson
    • 1
  • Krista S. Crider
    • 1
  • Richard S. Olney
    • 1
  1. 1.National Center on Birth Defects and Developmental DisabilitiesCenters for Disease Control and PreventionAtlantaUSA

Personalised recommendations